NCT04034134CompletedPhase 2
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd2 sites in 1 country111 target enrollmentStarted: November 18, 2019Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 111
- Locations
- 2
- Primary Endpoint
- Effective rate
Study Overview
Brief Summary
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years age or older ,male or female；
- •Alopecia areata diagnosed clinically；
- •Patients with alopecia accounting for 50% or more of the total scalp area and stable for at least 6 months or more；
- •Patients can complete treatment for at least six months；
- •Requirements for pregnant or lactating female and male and female of childbearing age；Female patients must be satisfied：Menopause (defined as no menstruation for at least one year);Or have been surgically sterilized；Or have fertility, but must satisfy：Pregnancy tests conducted within 7 days before randomization must be negative；And agree to use appropriate contraceptive methods throughout the trial period, including at least one barrier method；And no breastfeeding；Male patients must agree to use appropriate contraceptive measures throughout the trial, including at least one barrier method；
- •Patients are voluntarily enrolled in the Study and can be treated and visited according to the requirements of the protocol after signing the Informed Consent Form；
Exclusion Criteria
- •Alopecia caused by syphilitic alopecia, thyroid disease, trichotilomania, head moss, connective tissue disease, infection, zinc deficiency and iron deficiency;
- •Patients with acute diffuse alopecia areata (ADTAFS)
- •Patients with active tuberculosis
- •The following diseases were combined within 6 months before randomization:thyroid diseases ，liver diseases, malnutrition, heart diseases, nervous system diseases, gastrointestinal disorders, tumors and psychiatric diseases
- •HIV positive, active hepatitis B virus positive (HBsAg or HBeAg positive) and HCV-RNA positive at screening；
- •Other patients with abnormal history or clinical manifestations that may affect participants participation in the study or may confuse the results of the study；
- •Within two weeks before randomization，Patients who received glucocorticoid topical therapy, anthracene ointment, minoxidil, SADBE/DPCP contact immunotherapy, photochemotherapy or cryotherapy；
- •Before randomization，oral or injected any medicines to treat hair loss (including the glucocorticoids was detected in injection, systemic corticosteroids, antihistamines, stephania drugs, glycyrrhizin, glycine, methionine compound tablet, compound glycyrrhizin glucoside) and other liquorice extract, ring spore element, anti TNF antibody, IFN - gamma, IL - 2 antibodies, for alopecia areata therapy of traditional Chinese medicine and other JAK inhibitor) and washout period less than seven half-life of patients;
- •Participants in a clinical trial of any drug or medical device within 4 weeks prior to randomization.
Arms & Interventions
Jaktinib Hydrochloride Tablets 50mg bid
Experimental
Oral tablet for 24 weeks
Intervention: Jaktinib Hydrochloride Tablets (Drug)
Jaktinib Hydrochloride Tablets 150mg qd
Experimental
Oral tablet for 24 weeks
Intervention: Jaktinib Hydrochloride Tablets (Drug)
Jaktinib Hydrochloride Tablets 200mg qd
Experimental
Oral tablet for 24 weeks
Intervention: Jaktinib Hydrochloride Tablets (Drug)
Outcomes
Primary Outcomes
Effective rate
Time Frame: From randomization of the first subject until the last subject complete 6 months treatment
Effective rate = (cure + obvious effect + effective)/total cases \*100%;
Secondary Outcomes
- SALT score change(From randomization of the first subject until the last subject complete 6 months treatment)
- Quality of Life (AASIS)(From randomization of the first subject until the last subject complete 6 months treatment)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphocytic Leukemia (B-CLL)NCT00328198Genzyme, a Sanofi Company86
Unknown
Phase 2
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerColorectal CancerNCT04733963Second Affiliated Hospital, School of Medicine, Zhejiang University112
Withdrawn
Phase 2
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisRelapsing Multiple SclerosisNCT05496894CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Active, not recruiting
Phase 2
A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaNCT06423885Sichuan Baili Pharmaceutical Co., Ltd.64
Recruiting
Phase 2
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast CancerNCT06492005Mabwell (Shanghai) Bioscience Co., Ltd.160